第二条 员工持股计划遵循的基本原则 （一）依法合规原则 公司实施本期员工持股计划，严格按照法律、行政法规的规定履行程序，真 实、准确、完整、及时地实施信息披露。任何人不得利用本期员工持股计划进行 内幕交易、操纵证券市场等证券欺诈行为。 河南太龙药业股份有限公司第四期员工持股计划管理办法 河南太龙药业股份有限公司 第四期员工持股计划管理办法 第一章 总则 第一条 为规范河南太龙药业股份有限公司（以下简称"太龙药业"或"公 司"）第四期员工持股计划（以下简称"本期员工持股计划"或"本计划"）的实 施，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以下简称"中国 证监会"）《关于上市公司实施员工持股计划试点的指导意见》（以下简称"《指导 意见》"）、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》（以下 简称"《规范运作》"）等有关法律、行政法规、规章、规范性文件和《河南太龙 药业股份有限公司章程》、《河南太龙药业股份有限公司第四期员工持股计划（草 案）》之规定，特制定本管理办法。 第二章 员工持股计划的制定 （二） ...

河南太龙药业股份有限公司监事会 关于公司第四期员工持股计划相关事项的审核意见 河南太龙药业股份有限公司(以下简称"公司")监事会根据《公 司法》、《证券法》、《关于上市公司实施员工持股计划试点的指导 意见》（以下简称"《指导意见》"）、《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等相关文件的要求，认真审阅了 公司第四期员工持股计划的相关事项，并经全面充分的讨论与分析， 就公司第四期员工持股计划相关事项发表如下审核意见： （一）公司本期员工持股计划符合《公司法》、《证券法》、《指 导意见》等法律、法规、规范性文件和《公司章程》的规定，不存在 禁止实施员工持股计划的情形； （二）公司实施员工持股计划有利于完善公司员工和全体股东的 利益共享和风险共担机制，建立健全长效激励机制，充分调动管理者 和员工的积极性和创造性，吸引和保留优秀人才，提升员工的凝聚力 和公司竞争力，促进公司健康、持续发展，不存在损害公司及全体股 东利益的情形； （三）公司本期员工持股计划遵循"依法合规"、"自愿参与"、 "风险自担"的原则，不存在以摊派、强行分配等方式强制员工参与 的情形； （四）公司本期员工持股计划拟定的持有人 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2023-048 河南太龙药业股份有限公司 第九届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 河南太龙药业股份有限公司（以下简称"公司"）第九届董事会第 十八次会议于 2023 年 10 月 17 日在公司一楼会议室以现场结合通讯 的方式召开。会议通知已于 2023 年 10 月 12 日送达各位董事、监事。 本次会议应出席董事 9 人，实际出席董事 9 人，其中副董事长李景亮 先生和独立董事方亮先生以通讯方式出席。会议由董事长尹辉先生召 集并主持，全体监事列席了会议。会议的召集、召开及表决程序符合 有关法律、法规和《公司章程》的规定，所作决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于<河南太龙药业股份有限公司第四期员工 持股计划（草案）>及其摘要的议案》 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn） 的《河南太龙药业股份有限公司第四期员工持股计划（草案）》及其 摘要。 表 ...

河南太龙药业股份有限公司第四期员工持股计划（草案） 证券代码：600222 证券简称：太龙药业 河南太龙药业股份有限公司 第四期员工持股计划 （草案） 河南太龙药业股份有限公司 2023 年 10 月 1 河南太龙药业股份有限公司第四期员工持股计划（草案） 声 明 河南太龙药业股份有限公司第四期员工持股计划（草案） 风险提示 1、河南太龙药业股份有限公司本期员工持股计划须经公司股东大会批准后 方可实施，本期员工持股计划能否获得股东大会批准，存在不确定性； 2、有关本期员工持股计划的具体实施方案属初步结果，能否完成实施，存 在不确定性； 3、员工遵循依法合规、自愿参与、风险自担的原则，本期员工持股计划存 在不能成立的风险； 4、公司股票价格受宏观经济周期、国际/国内政治经济形势、投资者心理、 公司经营业绩等多种复杂因素影响。因此，股票交易是有一定风险的投资活动， 投资者对此应有充分准备。 敬请广大投资者谨慎决策，注意投资风险。 3 河南太龙药业股份有限公司第四期员工持股计划（草案） 本公司及董事会全体成员保证本期员工持股计划不存在虚假记载、误导性陈 述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

河南太龙药业股份有限公司独立董事 关于第九届董事会第十八次会议审议相关事项的独立意见 作为河南太龙药业股份有限公司(以下简称"公司")的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人 民共和国证券法》（以下简称《证券法》）、《上市公司独立董事管 理办法》、《关于上市公司实施员工持股计划试点的指导意见》（以 下简称《指导意见》）、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》（以下简称《监管指引第 1 号》）等法律、法规、 规范性文件以及《公司章程》的有关规定，我们基于独立、认真、谨 慎的立场，现就公司第九届董事会第十八次会议审议的员工持股计划 相关事项发表如下独立意见： （一）公司本期员工持股计划符合《公司法》、《证券法》、《指 导意见》、《监管指引第 1 号》以及其他法律、法规、规范性文件和 《公司章程》的规定，不存在禁止实施员工持股计划的情形。 （二）公司实施本期员工持股计划，有利于完善公司员工和全体 股东的利益共享和风险共担机制，建立健全长效激励机制，充分调动 管理者和员工的积极性和创造性，吸引和保留优秀人才，提升员工的 凝聚力和公司竞争力，促进公司健康、持续发展， ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2023-046 河南太龙药业股份有限公司 关于收到政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 河南太龙药业股份有限公司（以下简称"公司"）及下属子公司 自 2023 年 7 月 1 日至 2023 年 9 月 30 日累计收到政府补助肆佰零玖 万零叁拾玖元捌角陆分（4,090,039.86 元），占公司最近一期经审 计归属于上市公司股东的净利润绝对值的 5.67%。具体明细如下： 单位：元 币种：人民币 序号 获得时间 补助项目 补助类型 补助金额 收款单位 1 2023 年 7 月 13 日 企业房租租金返还 收益相关 739,506.18 新领先（重庆）医 药科技有限公司 2 2023 年 7 月 20 日 重庆市一次性吸纳就业补 贴 收益相关 100,000.00 新领先（重庆）医 药科技有限公司 3 2023 年 7 月 20 日 企业稳岗扩岗补贴 收益相关 15,500.00 桐君堂药业宁波有 限公司 4 2023 ...

证券代码：600222 证券简称：太龙药业 公告编号：2023-045 河南太龙药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2023 年 09 月 11 日(星期一) 上午 11:00- 12:00 ● 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于 2023 年 09 月 04 日(星期一) 至 09 月 08 日(星 期五)16:00 期间登录上证路演中心网站首页点击"提问预征集"栏目 进行提问， 或 将问题以电子邮件形式发送至 公司邮箱 600222@taloph.com。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南太龙药业股份有限公司（以下简称"公司"）已于 2023 年 8 月 19 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年上半年经营成果、 ...

证券代码：600222 证券简称：太龙药业 编号：临 2023-044 河南太龙药业股份有限公司 关于为下属全资公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称：浙江桐君堂中药饮片有限公司（以下简称"中 药饮片公司"）。 本次担保金额及已实际为其提供的担保余额：本次担保金额为 5,000 万元；截至本公告日，河南太龙药业股份有限公司（以下简称 "公司"）及下属子公司已实际为中药饮片公司提供的担保余额为 9,480 万元(含本次)。 本次担保是否有反担保：无 对外担保逾期的累计数量：无 一、担保情况概述 公司（包括子公司）在 2023 年度为子公司在银行申请的综合授信提 供不超过 38,000 万元的连带责任担保，其中对中药饮片公司的预计 担保额度为 13,000 万元。具体内容详见公司分别于 2023 年 4 月 7 日、 2023 年 6 月 22 日在上海证券交易所网站（www.sse.com.cn）披露的 相关公告（公告编号：临 2023-015 号、2023-030 ...

Financial Performance - The company's operating revenue increased by 15.08% year-on-year, primarily due to a surge in demand for heat-clearing and detoxifying drugs, resulting in a significant increase in sales compared to the previous year[19]. - The revenue from the pharmaceutical formulation business grew by 91.04% year-on-year, driven by successful bids in inter-provincial alliance procurement and the continuous enrichment of the traditional Chinese medicine product pipeline[19]. - The net profit attributable to shareholders decreased by 12.9 million yuan, mainly due to increased R&D personnel in research branches and higher investments in high-end formulations and improved new drug projects[19]. - The net cash flow from operating activities decreased by 21.62 million yuan year-on-year, attributed to increased personnel reserves and R&D investments in the pharmaceutical R&D service business[19]. - Basic earnings per share for the reporting period were -0.0677 yuan, compared to -0.0452 yuan in the same period last year[19]. - The diluted earnings per share for the reporting period were -0.0677 yuan, consistent with the basic earnings per share[19]. - The weighted average return on net assets was -2.49%, compared to -1.51% in the same period last year[19]. - The weighted average return on net assets, after deducting non-recurring gains and losses, was -2.62%, compared to -0.91% in the same period last year[19]. - The net profit attributable to shareholders was a loss of ¥38,331,796.75, compared to a loss of ¥25,432,310.28 in the previous year, indicating a worsening financial performance[20]. - The net cash flow from operating activities was a negative ¥88,001,824.00, compared to a negative ¥66,380,836.05 in the same period last year, reflecting increased cash outflows[20]. - The total assets decreased by 5.69% to ¥3,395,367,101.76 from ¥3,600,184,129.95 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 9.65% to ¥1,418,871,940.83 from ¥1,570,479,281.96 at the end of the previous year[20]. - The company achieved a revenue of 993.91 million yuan in the reporting period, representing a year-on-year growth of 15.08%[42]. - The pharmaceutical formulation business focused on brand building and product structure enhancement, leading to increased market share and sales growth in key products such as Danshen oral liquid and pediatric cough syrup[42]. - The company reported a total comprehensive loss of ¥79,162,210.83 for the first half of 2023, compared to a loss of ¥29,807,692.69 in the previous year[139]. - The company reported a significant increase in sales expenses, which rose to ¥99,791,558.32, up 42.9% from ¥69,823,969.20 in the previous year[134]. Research and Development - Research and development expenses surged by 77.46% to ¥79,750,330.93, up from ¥44,939,144.73, indicating a significant investment in new product development[50]. - The company has 199 ongoing research projects, with 20 submitted for registration, 4 obtaining production registration, and 2 passing consistency evaluations during the reporting period[44]. - The company launched 29 new generic drug projects and 14 improved new drug projects in 2023, with a total of 151 ongoing independent research projects by the end of the reporting period[46]. - The company’s clinical CRO services include comprehensive support for clinical research, from protocol design to data management and statistical analysis[29]. - The company is leveraging its technological platform and investment cooperation to build a comprehensive lifecycle management service system for pharmaceuticals[29]. - The company is actively investing in high-quality projects within the healthcare sector, while remaining vigilant about external economic and regulatory changes that could impact investment returns[71]. Market Position and Strategy - The company operates in the pharmaceutical manufacturing and R&D services sectors, focusing on traditional Chinese medicine and various drug formulations[24]. - The company has over 700 varieties and 1,100 specifications of traditional Chinese medicine pieces, enhancing its competitive edge through value-added services[25]. - The sales model includes a combination of distribution and direct sales, with a marketing network established across more than 30 provinces in China[27]. - The company emphasizes a transparent and safe medication process through technology integration in its traditional Chinese medicine services[28]. - The company has been recognized as one of the "Top 100 Chinese Pharmaceutical Enterprises" and has received multiple honors, including being named a key leading enterprise in Henan Province for 2022-2024[35]. - The company is positioned to benefit from the increasing demand for CRO services, with an expected investment in pharmaceutical R&D in China reaching USD 47.6 billion by 2024, including USD 32.1 billion for clinical stage R&D[34]. Financial Management and Investments - The company completed the establishment of a 400 million yuan pharmaceutical industry fund, with an initial investment of 120 million yuan, to enhance capital operation capabilities[46]. - The company has received 7 domestic patent authorizations during the reporting period, including 3 invention patents[46]. - The company is actively expanding its investment opportunities in the healthcare industry, linking with market investment institutions to explore new growth points[46]. - The company has implemented a comprehensive quality control system in production, adhering to GMP requirements and enhancing operational efficiency[43]. - The company has maintained a 100% compliance rate in external product inspections, ensuring a strong market reputation[40]. Environmental and Social Responsibility - The company is listed as a key pollutant discharge unit in Zhengzhou for 2023, focusing on water environment management[82]. - The company reported a chemical oxygen demand (COD) discharge of 0.91322 tons in the first half of 2023, well below the permitted limit of 100 mg/l[84]. - The company has established an emergency response plan for environmental incidents, updated in May 2022[88]. - The company has implemented a self-monitoring scheme for environmental pollutants, with third-party monitoring confirming compliance with discharge standards[89]. - The company invested 334,600 yuan in poverty alleviation and rural revitalization projects, benefiting 173 individuals through industry and employment support[99]. Corporate Governance and Compliance - The company has committed to not engaging in any competitive activities with Tai Long Pharmaceutical and its subsidiaries during the reporting period[101]. - The company has ensured the independence of Tai Long Pharmaceutical's operations, maintaining separate personnel, assets, finances, and business[102]. - The company will not utilize its shareholder status to seek preferential treatment for itself or its affiliates in business dealings with Tai Long Pharmaceutical[101]. - The company has established a commitment to avoid competition with Tailong Pharmaceutical in any form within or outside China[105]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant overdue debts[107]. Shareholder Information - The company had 56,015 common stock shareholders as of the end of the reporting period[118]. - The largest shareholder, Zhengzhou Tairong Industrial Investment Co., Ltd., held 14.37% of the shares, totaling 82,441,168 shares[120]. - Shareholder Wu Lan reduced his holdings by 5,842,200 shares, holding a total of 28,694,296 shares, representing 5.00%[120]. - The company reported a capital increase of 42,067,787.15 CNY from owner contributions during the current period[155]. - The total capital reserve at the end of the period is 750,255,579.20 CNY, which remains stable compared to the previous period[155]. Risk Management - The company faces significant industry policy risks due to the evolving regulatory landscape in the pharmaceutical sector, which has intensified market competition[68]. - Quality risk management is a priority, with the implementation of a comprehensive quality traceability system to ensure drug safety and efficacy throughout the production process[70]. - Research and development risks are acknowledged, with a commitment to enhancing the R&D team and decision-making processes to mitigate potential project delays and failures[71]. - The company is closely monitoring raw material prices and supply risks, which are influenced by various factors, including climate and environmental regulations, to manage operational costs effectively[70].

Group 1: Event Details - The event is scheduled for May 18, 2023, from 16:00 to 17:20 [1] - It will be held online via "全景·路演天下" platform [1] - The theme of the event is "Sincere Communication, Delivering Value" [1] Group 2: Participants - The attendees include General Manager Mr. Luo Jianchao, Board Secretary Ms. Feng Haiyan, and Financial Officer Mr. Zhao Hailin [1] - Participation may be adjusted due to special circumstances [1] Group 3: Company Commitment - The board guarantees the announcement's content is free from false records, misleading statements, or significant omissions [1] - The board takes legal responsibility for the truthfulness, accuracy, and completeness of the content [1]